



CASE WESTERN RESERVE
UNIVERSITY
SCHOOL OF MEDICINE



University Hospitals
Case Medical Center

*Department of Reproductive Biology
Case School of Medicine*

*Department of Obstetrics and Gynecology
University Hospitals*

Departmental Research Funding

- Cheung B (PI), **Gangestad AK**, The Appearance of Cesarean Section Wounds by Ultrasound Imaging, 2005 – ongoing, Biomet Orthopedics, Inc.
- Cheung B (PI), **Gangestad AK**, The Effects of Autologous Platelet Gel Use at Cesarean Section Closure on Postoperative Wound Healing and Recovery, 2005 – ongoing, Biomet Orthopedics, Inc.
- Colby K (PI), **Waggoner, SE** (Medical Advisor), Patient Navigator Video Training for Cancer in Low-Income African Americans, #1R43CA124328-01, National Cancer Institute, total budget \$99,643, Pending
- Colby K (PI), **Waggoner, SE** (Medical Advisor), Latino Faith-Based Cancer Outreach, R44 CA101557, NCI, total budget \$783,896, Pending
- Gass M (PI), **Liu JH**, Clinical Centers for the Clinical Trial and Observational Study of the Women's Health Initiative – East, 09/30/94 - 09/14/05, NIH, Direct Costs: \$10,428,075.
- Gass M (PI), **Liu JH**, Women's Health Initiative Memory Study (WHIMS), 09/30/94 -09/14/05, NIH, Direct Costs: \$212,070.
- Gorodeski, G** (PI), Estrogen and aging effects on transvaginal transport, 06/01/99– 05/31/08, NIH RO1 AG015955-06, Direct Costs: \$1,250,000.
- Greenfield, M** (PI), **Lazebnik N**, The effects of chemotherapy on ovarian structure and function, General Clinical Research Center (Horowitz R, PI), 01/01/04 – 12/31/05, NIH, M01 RR000080-42, Direct Costs: \$9,318.
- Herbst A (PI), **Waggoner, SE**, Continuation of Follow-up of DES-Exposed Cohorts, 2000-2005, NIH/NCI N01 CP 51018, \$163,300.
- Janata J** (Co-PI) A controlled study of an interdisciplinary pain management approach led by primary care physicians, The 4PCP trial (Primary Practice Program for Patients with Chronic Pain). The Josiah Macy Foundation. \$983,076, 2004-2007.
- Kingsberg S** (PI), **Liu JH**, Arredondo FA, A Study to Evaluate the Efficacy and Safety of Transdermal Patches Delivering Hormone Therapy in Menopausal Women with Low Libido, 7/19/2004 – ongoing, Proctor and Gamble Pharmaceuticals, \$61,497.
- Kingsberg S** (PI), **Liu JH**, **Gangestad AK**, A Trial of the Efficacy and Safety of Pharmacological Therapy in Women with Mixed Desire/Interest/Arousal/Orgasm Disorders, Zestra Laboratories, \$30,450, Pending.
- Kingsberg, S** (PI), Arredondo FA A Trial To Compare The Effects Of Hormone Therapy On The Vaginal Bleeding Pattern, Sexual Desire and Arousal in Postmenopausal Women with Sexual Dysfunction, Organon. 07/28/04 – 12/31/05, \$112,500.
- Kinsella T (PI), **Waggoner, SE** (Co-PI), Phase I/II Trial of intravenous TRIAPINE (NSC # 663249) in combination with pelvic radiation therapy and with or without weekly intravenous Cisplatin chemotherapy for locally advanced cervical cancer or pelvic

gynecologic malignancy, 2005 – ongoing, NCI Division of Cancer Treatment and Diagnosis (CTEP), Direct Costs: \$67,610.

- Liu JH** (PI), A Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile Hormone Administered Intravenously or Subcutaneously in Anovulatory or Oligoovulatory Infertile Females, 1/19/05 - 12/31/05, Ferring Pharmaceuticals, \$58,494.
- Liu JH** (PI), Arredondo FA, **Gangestad AK**, A Comparison of Multiple Doses of Hormones in Combination and Alone, in Relieving Vasomotor Symptoms in Postmenopausal Women - 8/12/05 – 12/31/05, Solvay Pharmaceuticals, \$95,250.
- Liu JH** (PI), Arredondo FA, A Trial to Demonstrate the Safety and Efficacy of Daily Hormone for the Treatment of Vasomotor Symptoms in Postmenopausal Women, 11/17/05 – 12/31/05, Duramed Research, \$75,000.
- Liu JH** (PI), Arredondo FA, A Trial to Evaluate the Efficacy and Safety of Synthetic Hormone for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women, 3/16/05 – 12/31/05, Duramed Research, \$104,625.
- Liu JH**. (PI), **Kingsberg S**, A Phase III Study to Evaluate the Efficacy and Safety of Transdermal Hormone Therapy in Women with Hypoactive Sexual Desire Disorder, 6/20/02 – ongoing, Proctor and Gamble Pharmaceuticals, \$102,952.
- Liu JH**. (PI), **Kingsberg S**, A Phase III Study to Evaluate the Efficacy and Safety of Transdermal Hormone Therapy Naturally Menopausal Women with Hypoactive Sexual Desire Disorder, 6/20/02 – ongoing, Proctor and Gamble Pharmaceuticals, \$131,425.
- Liu JH** (PI), Loret de Mola, JR, Arredondo FA, **Gangestad AK**, Clinical Contraceptive Trials Network-Female, 04/01/04 - 03/31/10, NIH, Direct Costs: \$3,900,000.
- Mesiano, S** (PI), Interaction Between Progesterone and Estrogen in the Control of Human Parturition, 06/01/05 – 05/31/08; March of Dimes, Direct Costs: \$219,254.
- Mesiano, S** (PI), Myometrial PRs/ERs: Targets for the Prevention of Preterm Labor, 2/01/06 – 1/31/08, NIH R03 HD051563, Direct Costs: \$100,000
- Prokopczyk B** (PI), **Waggoner, SE**, The Role of Polyaromatic Hydrocarbons and Tumor Specific Nitrosamines in Cervical Cancer. Project 4 Tobacco Carcinogenesis and Chemoprevention, 2001-2005, NIH PO1 CA70972, \$2,122,872 (\$45,379/ yr. for Case Western Reserve Subcontract).
- Rote, N** (PI), Antiphospholipid Antibody Heterogeneity, 7/1/03 – 4/30/08, NIH, RO1 HD043566-01A1, \$1,125,000 in Direct Costs
- Rote, N** (PI), Antibody-directed Targeting of Ovarian Cancer Blood Vessels, 03/15/06 – 03/14/08, OROC (Out Run Ovarian Cancer) Advocacy and Research Group, \$26,000 in Direct Costs
- Rote, N** (PI), Placental Endogenous Retrovirus Expression, 2/1/03 – 1/31/06, NIH, RO3 HD043546-(01-02), \$100,000 in Direct Costs
- Rote, N** (PI), Trophoblast Intercellular Fusion, 4/1/08 – 3/31/10, NIH, R21 HD052803, \$275,000 in Requested Direct Costs, Pending
- Rote, N** (PI), Apoptosis and Cytotrophoblast Differentiation, 4/1/08 – 3/31/11, NIH, RO1, \$750,000 in Requested Direct Costs, Pending
- Rote, N** (PI), Pathophysiology of Antiphospholipid Antibodies, 7/1/08 – 06/30/13, NIH, RO1 HD054693-01, \$1,250,000 in Requested Direct Costs, Pending
- Van Buren, G** (PI), A Study to Assess the Efficacy, Safety, and Tolerance of Hormone Gels in Preventing Preterm Delivery in Pregnant Women at Increased Risk for Preterm Delivery, 4/1/04 – present. Columbia Labs, \$225,300.
- von Gruenigen, VE** (PI), Lifestyle Change and Quality of Life in Obese Endometrial Cancer Survivors, 01/01/05 -12/31/06, Lance Armstrong Foundation, Direct Costs: \$110,000.

von Gruenigen, VE (PI), Support of the Gynecologic Cancer Patient, 04/01/04 -04/31/05, Stark County Community Foundation, Direct Costs: \$10,000.

von Gruenigen, VE (PI), The Recurrence of Early Endometrial Cancer in the Obese Patient, GOG/NCI, Pending.

von Gruenigen, VE (PI), A Phase II Trial of Carboplatin and Paclitaxel in Elderly Women with Ovarian Cancer, GOG/ NCI, Pending.

von Gruenigen, VE (PI), A Phase II randomized trial of BAY 43-9006, a Novel Raf Kinase Inhibitor, 2004-2005, NCI, Protocol # 6557.

von Gruenigen, VE (PI), Strategies to Improve the Quality of Life in Ovarian Cancer, 2005 – 2006, Gynecologic Cancer Foundation and Ovarian Cancer Research Grant, \$25,000.

von Gruenigen, VE (PI), Waggoner SE, A Trial For the Prevention of Doxil – related Palmar – Plantar Erythrodysesthesia, 2004 – ongoing, Therapeutics Division of Ortho-Biotech, Direct Costs: \$120,000.

Waggoner, SE (PI), **von Gruenigen, VE** (Co-PI), A Trial of Intravenous Medication as Post Chemotherapy Consolidation (Project 4 in Program for Ovarian, Fallopian tube and Peritoneal Carcinomas), 2002 – 2006, Unither Pharmaceuticals, Per capita reimbursement \$8,896.

Waggoner, SE (PI), Smoking Cessation Intervention for Women with Locally Advanced Cervical Carcinoma: A Pilot Study. NCI Division of Cancer Prevention, Pending.

Waggoner, SE (PI), GOG Clinical Trials, NIH CA27469-94, 7/1/04 – 3/21/07, \$100,000 per year average direct costs.

Wilson M (PI), **Liu JH**, Development and Application of a Drug Delivery Device, 07/01/01 -07/01/04, NIH SBIR Phase II Grant, Direct Costs: \$748,300.

Zanotti KM, Monk B. An Evaluation of Combined Therapy with Growth Factor Support in the Third Line Treatment of Recurrent or Persistent Ovarian or Primary Peritoneal Cancer. 2005-ongoing, GOG Protocol 0186.